Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway

Gaoran Xu; Junzhu Chen; Guorong Wang; Junhong Xiao; Ning Zhang; Yanyu Chen; Haoran Yu; Guangzhi Wang; Yongfu Zhao

doi:10.1016/j.omto.2019.12.010

Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway

Mol Ther Oncolytics. 2020 Jan 10:16:124-133. doi: 10.1016/j.omto.2019.12.010. eCollection 2020 Mar 27.

Authors

Gaoran Xu¹, Junzhu Chen¹, Guorong Wang¹, Junhong Xiao¹, Ning Zhang¹, Yanyu Chen¹, Haoran Yu¹, Guangzhi Wang¹, Yongfu Zhao¹

Affiliation

¹ Department of General Surgery, The Second Hospital of Dalian Medical University, Dalian 116000, China.

Abstract

Follicular thyroid carcinoma (FTC) is a common endocrine malignancy with highly aggressive features. In this study, next-generation sequencing technology was used to identify aberrant expression of sialyltransferase (ST) family members in FTC. Aberrant high expression of alpha-2,6-sialyltransferase 2 (ST6GAL2) was demonstrated to promote tumorigenesis of FTC in vitro and in vivo. Furthermore, ST6GAL2 promoted tumorigenesis by inactivating the Hippo signaling pathway. Resveratrol is a native compound extracted from Vitis species, and many studies have confirmed its protective cardiovascular and antineoplastic effects. Here we found that resveratrol can inhibit the tumorigenesis of FTC by suppressing the expression of ST6GAL2, further activating the Hippo pathway. In summary, this study revealed the role of the ST6GAL2-Hippo signaling pathway in FTC tumorigenesis and indicated that resveratrol, a commonly found antineoplastic compound, could inhibit tumorigenesis of FTC by regulating the abovementioned pathways.

Keywords: Hippo signaling pathway; follicular thyroid carcinoma; resveratrol; sialyltransferase families.